Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 43

recruiting
3 987
countries
28
conditions
2 109

869 trials match your criteria

Study of ifinatamab deruxtecan alone or in combination with other treatments for patients with metastatic castration-resistant prostate cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone

Dermatitis atopic

Not recruiting

Study on Rocatinlimab for Adults with Moderate-to-Severe Atopic Dermatitis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Rocatinlimab

Study on the Effectiveness and Safety of EYE103 Compared to Ranibizumab for Patients with Diabetic Macular Edema

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:EYE103

Psoriasis

Not recruiting

Study on the Effects and Safety of Piclidenoson for Patients with Moderate-to-Severe Plaque Psoriasis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Piclidenoson

Study on the Effectiveness of Durvalumab and BCG in Treating High-Risk, Non-Muscle Invasive Bladder Cancer in Patients New to BCG Treatment

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Durvalumab

Study on the Safety and Effectiveness of MK-1654 for Preventing Respiratory Syncytial Virus (RSV) in Healthy Pre-Term and Full-Term Infants

Registered drug
Countries:PolandPoland
  • Participants:0–17 years · Healthy volunteers

Obesity+1

Not recruiting

Study on the Effects of RO7204239 and Tirzepatide for Weight Loss in Patients with Obesity or Overweight with a Weight-Related Health Issue

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Tirzepatide

Study on the Safety and Tolerability of VRDN-003 for Patients with Thyroid Eye Disease

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:VRDN-003

Hidradenitis

Not recruiting

Study on the Effects of Remibrutinib for Adults with Moderate to Severe Hidradenitis Suppurativa

Registered drug
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Remibrutinib

Psoriasis

Not recruiting

Study on the Effectiveness and Safety of Tildrakizumab for Patients with Moderate to Severe Genital Psoriasis

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Tildrakizumab
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Capecitabine

Study Comparing BMS-986365 with Other Treatments for Patients with Metastatic Castration-resistant Prostate Cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.